PR-104A

CAT: 0804-HY-14572-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-14572-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PR-104A (SN 27858) is the alcohol metabolite of phosphate proagent PR-104. PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity[1]. PR-104A is metabolized under hypoxia by the 1-electron NADPH:cytochrome P450 oxidoreductase. PR-104A can be used for the research of relapsed/refractory T-lineage acute lymphoblastic leukemia (T-ALL) [2].
CAS Number
[680199-06-8]
Product Name Alternative
SN 27858
UNSPSC
12352005
Target
DNA Alkylator/Crosslinker; Drug Metabolite
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pr-104a.html
Purity
98.98
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
BrCCN(CCOS(=O)(C)=O)C1=C(C(NCCO)=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O
Molecular Formula
C14H19BrN4O9S
Molecular Weight
499.29
References & Citations
[1]Adam V Patterson, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007 Jul 1;13 (13) :3922-32.|[2]Donya Moradi Manesh, et al. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood. 2015 Sep 3;126 (10) :1193-202.|[3]McKeage MJ, et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer. 2011;11:432. Published 2011 Oct 7.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products